NorthWest Biotherapeutics Inc (NWBO)

[DocLee]

Meanwhile, we are continuing to focus on working with our teams of consultants on activities related to the review by the Medicines and Healthcare Products Regulatory Agency (MHRA) of our Marketing Authorization Application (MAA) in the UK, including preparations for inspections by the MHRA that are scheduled to take place in both the US and UK.

Does the fact that the update refers to scheduled inspections that are to take place in both the UK and the US signify that the FDA is even now actively assessing DCVax-L by "shadowing" the MHRA's process and that it may very rapidly adopt the MHRA's decision for the UK and issue its own MAA for DCVax-L for the US?